Do analysts rate SCNI or SXTP?

60 Degrees Pharmaceuticals has a consensus price target of $13.85, suggesting a potential upside of 835.81%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Scinai Immunotherapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 60 Degrees Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is SCNI or SXTP more profitable?

Scinai Immunotherapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. Company Net Margins Return on Equity Return on Assets Scinai Immunotherapeutics N/A N/A N/A 60 Degrees Pharmaceuticals -574.91% N/A -131.48%

Do analysts rate SCNI or CAPS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate SCNI or ALBT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SCNI or ALBT more profitable?

Company Net Margins Return on Equity Return on Assets Scinai Immunotherapeutics N/A N/A N/A Avalon GloboCare N/A N/A -74.36%

Do analysts rate SCNI or CELZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is SCNI or CELZ more profitable?

Scinai Immunotherapeutics' return on equity of 0.00% beat Creative Medical Technology's return on equity. Company Net Margins Return on Equity Return on Assets Scinai Immunotherapeutics N/A N/A N/A Creative Medical Technology N/A -88.38% -84.71%

Do analysts rate CUPR or SCNI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cuprina Holdings (Cayman) 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, CUPR or SCNI?

Cuprina Holdings (Cayman) has higher earnings, but lower revenue than Scinai Immunotherapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cuprina Holdings (Cayman) $40K 76.82 -$3.63M N/A N/A Scinai Immunotherapeutics $1.31M 0.70 -$8.31M -$1.06 N/A

Is CUPR or SCNI more profitable?

Company Net Margins Return on Equity Return on Assets Cuprina Holdings (Cayman) N/A N/A N/A Scinai Immunotherapeutics N/A N/A N/A

Scinai Immunotherapeutics (SCNI) Competitors

$0.23 -0.02 (-6.92%)

Closing price 07/24/2026 03:59 PM Eastern

Extended Trading

$0.24 +0.00 (+2.17%)

As of 07/24/2026 05:30 PM Eastern

Compare

SCNI vs. SXTP, CAPS, ALBT, CELZ, and CUPR

Should you buy Scinai Immunotherapeutics stock or one of its competitors? MarketBeat compares Scinai Immunotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scinai Immunotherapeutics include 60 Degrees Pharmaceuticals (SXTP), Capstone Therapeutics (CAPS), Avalon GloboCare (ALBT), Creative Medical Technology (CELZ), and Cuprina Holdings (Cayman) (CUPR). These companies are all part of the "pharmaceutical products" industry.

How does Scinai Immunotherapeutics compare to 60 Degrees Pharmaceuticals?

Scinai Immunotherapeutics (NASDAQ:SCNI) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

60 Degrees Pharmaceuticals has higher revenue and earnings than Scinai Immunotherapeutics. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31M	0.70	-$8.31M	-$1.06	N/A
60 Degrees Pharmaceuticals	$1.41M	2.79	-$7.36M	-$8.92	N/A

In the previous week, Scinai Immunotherapeutics had 1 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 2 mentions for Scinai Immunotherapeutics and 1 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 beat Scinai Immunotherapeutics' score of 0.44 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Scinai Immunotherapeutics	Neutral
60 Degrees Pharmaceuticals	Very Positive

Scinai Immunotherapeutics has a beta of 2.11, suggesting that its share price is 111% more volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.47, suggesting that its share price is 147% more volatile than the broader market.

60 Degrees Pharmaceuticals has a consensus price target of $13.85, suggesting a potential upside of 835.81%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Scinai Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Scinai Immunotherapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%.

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

60 Degrees Pharmaceuticals beats Scinai Immunotherapeutics on 9 of the 15 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Capstone Therapeutics?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Scinai Immunotherapeutics has a beta of 2.11, suggesting that its stock price is 111% more volatile than the broader market. Comparatively, Capstone Therapeutics has a beta of -1.51, suggesting that its stock price is 251% less volatile than the broader market.

Scinai Immunotherapeutics has higher earnings, but lower revenue than Capstone Therapeutics. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31M	0.70	-$8.31M	-$1.06	N/A
Capstone Therapeutics	$48.11M	0.07	-$21.23M	-$3.37	N/A

In the previous week, Scinai Immunotherapeutics had 1 more articles in the media than Capstone Therapeutics. MarketBeat recorded 2 mentions for Scinai Immunotherapeutics and 1 mentions for Capstone Therapeutics. Capstone Therapeutics' average media sentiment score of 1.87 beat Scinai Immunotherapeutics' score of 0.44 indicating that Capstone Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Scinai Immunotherapeutics	Neutral
Capstone Therapeutics	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are held by institutional investors. 60.9% of Scinai Immunotherapeutics shares are held by insiders. Comparatively, 39.3% of Capstone Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Scinai Immunotherapeutics has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. Scinai Immunotherapeutics' return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Capstone Therapeutics	-41.26%	-114.15%	-39.74%

Summary

Scinai Immunotherapeutics beats Capstone Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Avalon GloboCare?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Scinai Immunotherapeutics has a beta of 2.11, suggesting that its stock price is 111% more volatile than the broader market. Comparatively, Avalon GloboCare has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Avalon GloboCare	N/A	N/A	-74.36%

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are held by institutional investors. 60.9% of Scinai Immunotherapeutics shares are held by company insiders. Comparatively, 24.2% of Avalon GloboCare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Scinai Immunotherapeutics has higher revenue and earnings than Avalon GloboCare. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31M	0.70	-$8.31M	-$1.06	N/A
Avalon GloboCare	$1.26M	3.22	-$18.26M	-$3.51	N/A

In the previous week, Avalon GloboCare had 2 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 4 mentions for Avalon GloboCare and 2 mentions for Scinai Immunotherapeutics. Avalon GloboCare's average media sentiment score of 0.72 beat Scinai Immunotherapeutics' score of 0.44 indicating that Avalon GloboCare is being referred to more favorably in the news media.

Company	Overall Sentiment
Scinai Immunotherapeutics	Neutral
Avalon GloboCare	Positive

Summary

Scinai Immunotherapeutics beats Avalon GloboCare on 7 of the 11 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Creative Medical Technology?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Creative Medical Technology has lower revenue, but higher earnings than Scinai Immunotherapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31M	0.70	-$8.31M	-$1.06	N/A
Creative Medical Technology	$10K	383.94	-$5.99M	-$2.14	N/A

Scinai Immunotherapeutics' return on equity of 0.00% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Creative Medical Technology	N/A	-88.38%	-84.71%

Scinai Immunotherapeutics has a beta of 2.11, suggesting that its share price is 111% more volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market.

In the previous week, Scinai Immunotherapeutics and Scinai Immunotherapeutics both had 2 articles in the media. Creative Medical Technology's average media sentiment score of 1.45 beat Scinai Immunotherapeutics' score of 0.44 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Scinai Immunotherapeutics	Neutral
Creative Medical Technology	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 60.9% of Scinai Immunotherapeutics shares are held by company insiders. Comparatively, 1.0% of Creative Medical Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Scinai Immunotherapeutics beats Creative Medical Technology on 8 of the 12 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Cuprina Holdings (Cayman)?

Cuprina Holdings (Cayman) (NASDAQ:CUPR) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

Cuprina Holdings (Cayman) has a beta of -1.1, indicating that its stock price is 210% less volatile than the broader market. Comparatively, Scinai Immunotherapeutics has a beta of 2.11, indicating that its stock price is 111% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cuprina Holdings (Cayman) has higher earnings, but lower revenue than Scinai Immunotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cuprina Holdings (Cayman)	$40K	76.82	-$3.63M	N/A	N/A
Scinai Immunotherapeutics	$1.31M	0.70	-$8.31M	-$1.06	N/A

Company	Net Margins	Return on Equity	Return on Assets
Cuprina Holdings (Cayman)	N/A	N/A	N/A
Scinai Immunotherapeutics	N/A	N/A	N/A

In the previous week, Cuprina Holdings (Cayman) and Cuprina Holdings (Cayman) both had 2 articles in the media. Cuprina Holdings (Cayman)'s average media sentiment score of 1.43 beat Scinai Immunotherapeutics' score of 0.44 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the media.

Company	Overall Sentiment
Cuprina Holdings (Cayman)	Positive
Scinai Immunotherapeutics	Neutral

Summary

Scinai Immunotherapeutics beats Cuprina Holdings (Cayman) on 4 of the 7 factors compared between the two stocks.

Get Scinai Immunotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCNI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCNI vs. The Competition

Export

Metric	Scinai Immunotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$910K	$3.67B	$7.06B	$12.20B
Dividend Yield	N/A	2.19%	2.67%	9.41%
P/E Ratio	-0.22	21.29	27.14	23.63
Price / Sales	0.70	297.82	582.30	111.98
Price / Cash	N/A	153.89	49.81	58.78
Price / Book	0.29	7.88	10.28	6.01
Net Income	-$8.31M	$23.86M	$3.60B	$331.99M
7 Day Performance	-7.93%	-3.82%	-1.27%	-0.63%
1 Month Performance	-8.37%	-4.45%	-1.67%	-3.04%
1 Year Performance	-88.83%	33.01%	18.25%	13.30%

Scinai Immunotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCNI Scinai Immunotherapeutics	0.4886 of 5 stars	$0.23 -6.9%	N/A	-88.8%	$910K	$1.31M	N/A	20	Short Interest Increase Gap Down
SXTP 60 Degrees Pharmaceuticals	3.2296 of 5 stars	$1.52 -1.9%	$13.85 +811.2%	-71.8%	$4.12M	$1.41M	N/A	3
CAPS Capstone Therapeutics	0.7316 of 5 stars	$0.26 -2.5%	N/A	-85.6%	$4M	$48.11M	N/A	38
ALBT Avalon GloboCare	0.3127 of 5 stars	$0.31 +12.9%	N/A	-87.7%	$3.96M	$1.26M	N/A	5	Short Interest Increase
CELZ Creative Medical Technology	1.5116 of 5 stars	$0.86 +4.6%	N/A	-70.1%	$3.90M	$10K	N/A	5	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCNI) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scinai Immunotherapeutics (SCNI) Competitors

SCNI vs. SXTP, CAPS, ALBT, CELZ, and CUPR

How does Scinai Immunotherapeutics compare to 60 Degrees Pharmaceuticals?

Summary

How does Scinai Immunotherapeutics compare to Capstone Therapeutics?

Summary

How does Scinai Immunotherapeutics compare to Avalon GloboCare?

Summary

How does Scinai Immunotherapeutics compare to Creative Medical Technology?

Summary

How does Scinai Immunotherapeutics compare to Cuprina Holdings (Cayman)?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNI vs. The Competition

Scinai Immunotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scinai Immunotherapeutics (SCNI) Competitors

SCNI vs. SXTP, CAPS, ALBT, CELZ, and CUPR

How does Scinai Immunotherapeutics compare to 60 Degrees Pharmaceuticals?

Which has stronger valuation and earnings, SCNI or SXTP?

Does the media favor SCNI or SXTP?

Which has more volatility & risk, SCNI or SXTP?

Do analysts rate SCNI or SXTP?

Is SCNI or SXTP more profitable?

Do institutionals and insiders have more ownership in SCNI or SXTP?

Summary

How does Scinai Immunotherapeutics compare to Capstone Therapeutics?

Which has more risk and volatility, SCNI or CAPS?

Which has better valuation & earnings, SCNI or CAPS?

Does the media favor SCNI or CAPS?

Do analysts rate SCNI or CAPS?

Do insiders and institutionals have more ownership in SCNI or CAPS?

Is SCNI or CAPS more profitable?

Summary

How does Scinai Immunotherapeutics compare to Avalon GloboCare?

Which has more volatility and risk, SCNI or ALBT?

Is SCNI or ALBT more profitable?

Do insiders & institutionals have more ownership in SCNI or ALBT?

Do analysts rate SCNI or ALBT?

Which has preferable earnings and valuation, SCNI or ALBT?

Does the media favor SCNI or ALBT?

Summary

How does Scinai Immunotherapeutics compare to Creative Medical Technology?

Which has stronger valuation and earnings, SCNI or CELZ?

Is SCNI or CELZ more profitable?

Which has more volatility & risk, SCNI or CELZ?

Does the media refer more to SCNI or CELZ?

Do analysts rate SCNI or CELZ?

Do institutionals and insiders have more ownership in SCNI or CELZ?

Summary

How does Scinai Immunotherapeutics compare to Cuprina Holdings (Cayman)?

Which has more risk and volatility, CUPR or SCNI?

Do analysts rate CUPR or SCNI?

Do insiders and institutionals hold more shares of CUPR or SCNI?

Which has preferable valuation & earnings, CUPR or SCNI?

Is CUPR or SCNI more profitable?

Does the media prefer CUPR or SCNI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNI vs. The Competition

Scinai Immunotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools